STOCK TITAN

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Syndax Pharmaceuticals has granted inducement awards to ten new employees, allowing them to purchase up to 169,600 shares of common stock. The stock options will vest over four years, with 25% vesting after one year and the rest vesting monthly over 36 months.
Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Nov. 3, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on November 1, 2023 the Company granted inducement awards to purchase up to 169,600 shares of common stock to ten new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax

Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the Menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827 

Cision View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301977258.html

SOURCE Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals announced the granting of inducement awards to new employees.

The new employees can purchase up to 169,600 shares of common stock.

The stock options will vest over four years.

25% of the underlying shares will vest on the one-year anniversary of the vesting commencement date, and 1/48th of the underlying shares will vest monthly thereafter over 36 months.

The employee must maintain a continued service relationship with Syndax Pharmaceuticals through the applicable vesting dates.
Syndax Pharmaceuticals Inc

NASDAQ:SNDX

SNDX Rankings

SNDX Latest News

SNDX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Waltham

About SNDX

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.